|Day Low/High||0.07 / 0.08|
|52 Wk Low/High||0.07 / 0.35|
LAS VEGAS, Sept. 3, 2019 /PRNewswire/ -- GB Sciences, Inc.
LAS VEGAS, Aug. 28, 2019 /PRNewswire/ -- GB Sciences, Inc.
Education program includes evidence-based review of FDA-registered human clinical trial data supporting the use of cannabis to treat approved medical conditions.
In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars.
Oral thin films provide a convenient and accurate delivery system with increased bioavailability of cannabis active ingredients for patients LAS VEGAS, June 11, 2019 /PRNewswire/ -- GB Sciences, Inc.
GBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredients
Positioned to Increase Revenue by Approximately $5.6 Million
Here's what you need to know now for Sept. 24.
Marijuana is on the ballot in several states this election cycle, and its approval could be a boon for those in the business -- though obstacles remain.
Investors choosing among the hundreds of cannabis businesses are often caught in a conundrum as to whether medical companies are a safer investment compared to recreational businesses.
Companies in the cannabis business have an appetite for capital to fuel what has emerged as one of the largest growth sectors, and more investors are taking the risk.
Cannabis Cultivation Technology Arrives in Puerto Rico & Nevada
New Corporate Web Presence Showcases Three Operating Divisions
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.